Arca
Skip to content

AVTO5: Complete Response Letter

A complete response letter is FDA's decision not to approve an application as submitted. See BLA 761461's history or Alvotech USA's company page.

On Nov 26, 2025, FDA declined to approve AVTO5 (BLA 761461) from Alvotech USA Inc. in its present form, citing facility inspections, product quality. openFDA lists it as not yet approved.

  • Letter date: Nov 26, 2025
  • Application: BLA 761461
  • Since then: Not approved

What FDA Cited

FDA's own section headings in the letter; each finds other letters citing it

Facility inspectionsProduct quality

The Letter

Text from openFDA

(1) Following pre-license inspection of oe , listed in this application, FDA conveyed deficiencies to the representative of the facility. The facility should provide satisfactory responses to these deficiencies to the FDA office indicated on the FDA Form 483 p...… openFDA did not return the full text just now. Open it in the letter search.

Alvotech USA's Other Letters

Newest first
  • AVT06Nov 24, 2025 · BLA 761435 · not approved
  • AVTO5Oct 31, 2025 · BLA 761462 · not approved
  • AVT04Oct 11, 2023 · BLA 761343 · later approved
  • AVTO2Jun 28, 2023 · BLA 761299 · later approved
  • AVT02Dec 20, 2022 · BLA 761299 · later approved

Record

Company
Alvotech USA Inc.
Application
BLA 761461
Status in openFDA
Unapproved

FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.